about
Modulation of the Rho/ROCK pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity.The treatment of patients with 1-3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis.Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.Radiotherapy for adult medulloblastoma: Long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative programResected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy.Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.Transdermal buprenorphine for oropharyngeal mucositis-associated pain in patients treated with radiotherapy for head and neck cancer.Circulating tumour cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival.Could machine learning improve the prediction of pelvic nodal status of prostate cancer patients? Preliminary results of a pilot study.An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes.Three-dimensional conformal radiotherapy, static intensity-modulated and helical intensity-modulated radiotherapy in glioblastoma. Dosimetric comparison in patients with overlap between target volumes and organs at risk.Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines.Light and shadows of a new technique: is photon total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one?Clinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage III and IV diseaseClinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage I and II diseaseA benchmark study on 883 nasopharyngeal cancer patients treated in two Italian Centres from 1977 to 2000. Part I: evolving technical choices and survivalA benchmark study on 883 nasopharyngeal cancer patients treated in two Italian Centres from 1977 to 2000. Part II: evolving technical choices and toxicity patternsA national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study)Overexpression of sialidase NEU3 increases the cellular radioresistance potential of U87MG glioblastoma cellsExploring the Role of Enzalutamide in Combination with Radiation Therapy: An In Vitro StudyStereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort studyLong-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery
P50
Q30484563-322131CE-4EBD-461D-98B1-6F2B5C6ECECDQ35616014-7BCB4BF9-EEAC-4514-A9B7-1B6447BAEEEEQ38383388-4ADE7A83-64AB-4F4F-91BF-98B178A76553Q38537549-0159D513-5368-4E81-B88E-FCDD9E86E6B1Q39732809-42642747-4457-42FA-A70C-AB04FDDF351AQ41068116-66CD0EFF-AD50-47CA-97E6-FB67C71DC772Q43127876-91D29200-F717-4568-A76C-BCAD9B743E7AQ45844676-0EE2D50D-9064-43F8-9A77-80FDB60E1191Q45954421-8B21E91A-1A0C-44CF-8CCD-5906E1625DE8Q46799959-E2B56F1A-C963-47B5-A9F6-92315DA05726Q47099465-D5451C20-F0B5-40B6-A958-86315401C982Q48629409-80D2095F-68C2-4CF6-9C95-411DEAC3BA66Q51031963-C0EE9883-167E-4274-A3AD-435D8EAB40F0Q52788391-B1B851F3-1215-477C-987E-C10E04B5C84FQ58696459-66EBAB8A-A5EA-4DCF-B4CB-8E5AF8F9E9FAQ60547803-4ABDAF6B-E312-436E-B9BB-92FEC267A77AQ60547823-CDF8BEE5-AD12-4080-BCD5-CAD4134A609DQ60547871-4011BA1A-B500-44CE-8ED0-974EB9A78012Q60547873-02A0466A-55D1-4593-804C-FD3FAE592D98Q62693648-20BF5BD4-0930-43A9-B35B-3D1AA9B9343BQ64388773-A8E325AE-967A-47F6-961E-4DA377ED2F77Q88923645-FB735FAD-9734-4B41-8790-33C426FCE5AEQ90748402-F97EE0B5-1E48-461B-8FDC-1161BBDF24E2Q91266225-577FA945-0B8A-48DE-82FB-BC76A2CE8A69
P50
description
researcher (ORCID 0000-0001-5720-0079)
@en
wetenschapper
@nl
name
Nadia Pasinetti
@en
Nadia Pasinetti
@nl
type
label
Nadia Pasinetti
@en
Nadia Pasinetti
@nl
prefLabel
Nadia Pasinetti
@en
Nadia Pasinetti
@nl
P31
P496
0000-0001-5720-0079